TVWM
VRTX icon

Tower View Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Tower View Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,193
Closed -$2.31M – 200
2025
Q2 		$2.31M Buy
5,193
+63
+1% +$29K 1.2% 32
2025
Q1 		$2.49M Sell
5,130
-2
-0% -$932 1.45% 32
2024
Q4 		$2.07M Buy
5,132
+245
+5% +$114K 1.09% 38
2024
Q3 		$2.27M Buy
4,887
+80
+2% +$38.4K 1.24% 37
2024
Q2 		$2.25M Buy
4,807
+33
+0.7% +$14.3K 1.29% 36
2024
Q1 		$2M Buy
4,774
+33
+0.7% +$13.9K 1.17% 37
2023
Q4 		$1.93M Buy
4,741
+59
+1% +$21.8K 1.2% 37
2023
Q3 		$1.63M Buy
4,682
+14
+0.3% +$4.9K 1.14% 36
2023
Q2 		$1.64M Buy
+4,668
New +$1.57M 1.11% 37
2021
Q2 		– Sell
-6,526
Closed -$1.4M – 202
2021
Q1 		$1.4M Buy
6,526
+227
+4% +$49.9K 0.77% 47
2020
Q4 		$1.49M Buy
6,299
+85
+1% +$19.5K 0.85% 47
2020
Q3 		$1.69M Buy
6,214
+105
+2% +$29K 1.1% 38
2020
Q2 		$1.77M Buy
+6,109
New +$1.66M 1.3% 38

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Tower View Wealth Management's VRTX Position: Q3 2025 in Review

Tower View Wealth Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 5,193 shares — an estimated $2.31M sold.

Tower View Wealth Management first reported a position in VRTX in Q2 2020 and held it in 13 quarters. The position peaked at $2.49M in Q1 2025. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

  • Tower View Wealth Management reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Tower View Wealth Management sold 5,193 Vertex Pharmaceuticals shares in Q3 2025, an estimated $2.31M.
  • Tower View Wealth Management first reported a position in Vertex Pharmaceuticals in Q2 2020 and held it in 13 quarters.
  • Tower View Wealth Management's Vertex Pharmaceuticals position peaked at $2.49M in Q1 2025.
  • 1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on Tower View Wealth Management's 13F filing for Q3 2025, filed 16 Oct 2025.